Register for free to
view the full innovation profile.
Dronedarone is an FDA-approved drug that has shown anti-cancer activity in breast cancer cell cultures, sphere forming assays and in mice
About
Background Effective and well-tolerated novel therapies are needed for the treatment of breast cancer and other cancers. Unfortunately, the length of time required to develop a new drug is increasing, averaging approximately 14 years and costing US$1.8 billion. This long development period and high cost of new oncology drugs is largely due to unexpected problems once they reach testing in human clinical trials. Although drugs may appear to be effective in cell cultures and/or animal models, they often cause unacceptable toxic side effects in humans. Technology Overview Dronedarone is an FDA-approved oral drug that is used to treat patients with cardiac arrhythmias but has shown anti-cancer activity in breast cancer cell cultures, sphere forming assays and in mice. Given its established safety profile and pre-clinical efficacy data, Dronedarone offers a tantalizing opportunity for drug re-purposing as a potential anti-cancer agent, primarily through its effects on the induction of apoptosis and MYC inhibition. Stage of Development: Proof of principle data available. #15-060
Applications
• Novel, oral anti-cancer agent for breast cancer and other cancers.